ReviewCalcified tissue international2026
Impact of Beta-Blocker Therapy for Cardiovascular Diseases on Bone Healing Following Fracture Surgery.
Review in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fracture healing is a complex biological process influenced by systemic conditions and medications. Given the high prevalence of cardiovascular disease in fracture surgery patients and the use of beta-blockers, evidence linking beta-adrenergic signaling to bone metabolism has raised interest in their effects on postoperative healing. This narrative review synthesizes experimental, translational, and clinical evidence regarding the impact of beta-blocker therapy on fracture healing. A structured literature-based approach was used to evaluate studies addressing β-adrenergic signaling in cardiovascular regulation, bone cell function, angiogenesis, and postoperative fracture outcomes. Both preclinical models and observational human studies were critically analyzed to identify mechanistic pathways and clinical associations. Experimental studies indicate that β-adrenergic signaling inhibits osteoblast activity and callus formation, enhances osteoclast activity, and impairs angiogenesis during bone repair. Beta-blockade, particularly with non-selective and lipophilic agents, may counteract these effects, thereby promoting bone formation and microvascular function in animal models. However, clinical evidence remains heterogeneous. Some observational studies report potential benefits, including reduced postoperative mortality or lower fracture risk, whereas other studies show no significant association with healing outcomes or suggest a possible increase in non-union risk. Confounding factors such as comorbid cardiovascular disease, polypharmacy, and differences in drug selectivity limit causal interpretation. Beta-blocker therapy may influence fracture healing through neurovascular and cellular pathways, but current clinical evidence is insufficient to confirm a definitive beneficial or harmful effect. Further prospective, mechanistic, and stratified clinical studies are required to clarify their role in optimizing both cardiovascular and skeletal outcomes in patients undergoing fracture surgery.
Indexed as
Identifiers
42501089What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.